The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.
The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.
Brian Koffman, MDCM, MSEd, provides insight from a patient’s perspective on self-advocacy and reflects on the positive direction in which the treatment paradigm of chronic lymphocytic leukemia (CLL) is heading.
Brian Koffman, MDCM, MSEd, shares insight on his current relapse of chronic lymphocytic leukemia (CLL) and discusses the potential value of chimeric antigen receptor (CAR) T-cell therapy, which he will be receiving in an upcoming clinical trial.
Brian Koffman, MDCM, MSEd, discusses his rejection of allogeneic stem cell transplant and development of chemorefractory chronic lymphocytic leukemia (CLL) that led to his participation in an early clinical trial of ibrutinib.